Propanc Biopharma Inc. has announced plans to investigate the phenomenon of "mesenchymal drift" as part of its ongoing research into novel treatments for chronic diseases, including recurrent and metastatic cancer. The company is focusing on how its lead product candidate, PRP-a combination of pancreatic proenzymes trypsinogen and chymotrypsinogen-may impact epithelial-to-mesenchymal transition (EMT) pathways, which are central to both cancer progression and fibrosis. Propanc is preparing to begin a Phase 1b First-In-Human study of PRP in patients with advanced solid tumors in 2026, with further Phase 2 trials planned. The scientific results are part of an expanding research program and have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596785-en) on December 04, 2025, and is solely responsible for the information contained therein.